The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Acute Coronary Syndromes brings NSTE-ACS and STEMI recommendations into a single, unified document. For interventional and consulting cardiologists, a few themes are worth carrying into daily decisions.
A unified ACS pathway. Combining NSTE-ACS and STEMI reflects how care actually flows, from first medical contact through revascularisation and secondary prevention.
Antiplatelet strategy. Twelve months of dual antiplatelet therapy remains a routine option, but the guideline also supports a shorter DAPT course followed by P2Y12-inhibitor monotherapy to reduce bleeding in eligible patients, and reinforces the more potent P2Y12 inhibitors (ticagrelor, prasugrel) as first-line over clopidogrel in ACS.
Complete revascularisation. A strategy of complete revascularisation is recommended in selected patients with multivessel disease; non-culprit lesions may be treated in the index procedure or staged.
Procedural strategies. Radial-first access is preferred over femoral to reduce bleeding, vascular complications and death, and intracoronary imaging (IVUS or OCT) is recommended to guide PCI of complex lesions.
Why it matters for central Gujarat: radial-first access and image-guided PCI are practical, lower-cost practices that improve safety, and a shorter potent-P2Y12 pathway can reduce bleeding risk for patients who travel long distances with variable follow-up.
Draft for review: this is a peer-level summary drawn from secondary sources. Please verify the exact class and level-of-evidence wording against the primary guideline (ACC.org; Circulation; JACC) before relying on it.